https://diabetesjournals.org/diabetes/article/59/6/1338/33418/Chronic-Rapamycin-Treatment-Causes-Glucose (increases FFAs and TGs). Can even increase glucose.
https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.109.140756
The effect of rapamycin and rapalogs on the cardiovascular system initially was not clear, especially in humans. In clinical studies with transplant patients, rapalogs induced a negative plasma cardiovascular risk profile, e.g., an increase in LDL cholesterol and triglyceride concentrations in plasma [47]. Rapamycin also has been reported to have deleterious effects on endothelial function (ability of a blood vessel to constrict and dilate) in laboratory animals and in human coronary arteries from sirolimus-eluting stents [48, 49]. Rapamycin also has been reported to accelerate senescence of endothelial progenitor cells [50]; however, as described below, most of the recent studies indicate that rapamycin reduces cellular senescence